Details for Patent: 10,729,739

Which drugs does patent 10,729,739 protect, and when does it expire?

Patent 10,729,739 protects FIRMAGON and is included in one NDA.

This patent has one hundred and three patent family members in twenty-four countries.

Summary for Patent: 10,729,739

Title:	Methods of treating prostate cancer with GnRH antagonist
Abstract:	The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Inventor(s):	Olesen; Tine Kold (New York, NY), Persson; Bo-Eric (St. Prex, CH), Cantor; Per (Charlottenlund, DK), van der Meulen; Egbert A (Dalby, SE), Jensen; Jens-Kristian Slott (Bagsvaerd, DK)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	15/405,552
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,729,739

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-001	Dec 24, 2008		RX	Yes	No						TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
Ferring	FIRMAGON	degarelix acetate	POWDER;SUBCUTANEOUS	022201-002	Dec 24, 2008		RX	Yes	Yes						TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT

International Family Members for US Patent 10,729,739

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009213748
Australia	2009213751
Brazil	PI0908127
Brazil	PI0908129